Overview

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

Status:
Withdrawn
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety, efficacy and pharmacokinetics profile of human monoclonal antibodies, BRII-196 and BRII-198 compared with placebo in patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Brii Biosciences, Inc.